Axsome amends Hercules loan: Tranche 3 raised to $80M, covenants eased

Axsome Therapeutics, Inc.

Fifth Amendment increases Tranche 3 commitment from $75M to $80M.
Availability periods extended: Tranche 1D to June 15, 2025; Tranche 1E to Dec 15, 2025.
Performance covenants restructured; new Performance Covenant D added.
Conditional waiver of $30M+ qualified cash requirement when market cap exceeds $1.5B.
Malta subsidiary permitted to request advances and hold more cash outside U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.